个人简介

Dr. Eric Nuermberger is an associate professor of medicine at the Johns Hopkins University School of Medicine. His areas of clinical expertise include infectious disease and tuberculosis. Dr. Nuermberger received his undergraduate degree in psychology from Kenyon University. He earned his M.D. from Vanderbilt. He completed his residency and a fellowship in infectious diseases at Johns Hopkins. His research interest includes the experimental chemotherapy of TB. He works with mice and other models to develop new, shorter drug regimens. Dr. Nuermberger is a member of several professional organizations, including the American Society for Microbiology and the American Thoracic Society.

研究领域

Tuberculosis drug development; Tuberculosis therapeutic vaccine development; Mycobacterium ulcerans disease (Buruli ulcer)

Dr. Nuermberger’s primary research interest is the experimental chemotherapy of TB. The work uses well-validated murine models of active TB and latent TB infection to evaluate the efficacy of promising new antimicrobials. A major goal is to identify new agents that can be combined with existing drugs to shorten the duration of TB therapy or allow more intermittent drug administration. He is also working with an innovative flow-controlled in vitro pharmacodynamic system to gain a better understanding of the pharmacodynamics of drug efficacy and selection of drug-resistant mutants during exposure to currently used agents. His secondary interest is the experimental chemotherapy of pneumonia caused by Streptococcus pneumoniae, the leading cause of community-acquired pneumonia in humans. The work uses a novel low-dose aerosol infection model that produces an isolated pneumonia in mice. This model may be particularly useful for evaluating the efficacy of antimicrobials that concentrate in the lung parenchyma relative to serum.

近期论文

查看导师最新文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Nuermberger E, Choi M, Scheel PJ, Moore R, Briggs WA. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int. 2000;58:1253-60. Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother. 2002;46:1875-9. Nuermberger E, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. 2004;169:421-6. 4. Nuermberger E, Yoshimatsu T, Tyagi S, Bishai WR, Grosset J. Paucibacillary tuberculosis in mice after prior aerosol immunization with BCG. Infect Immun. 2004;72:1065-71. Nuermberger EL,Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med. 2004;170:1131-4. Karakousis PC, Yoshimatsu T, Lamichhane G, Woolwine SC, Nuermberger EL,Grosset J, Bishai WR. Dormancy Phenotype Displayed by Extracellular Mycobacterium tuberculosis within Artificial Granulomas in Mice. J Exp Med. 2004;200:647-57. Nuermberger E, Bartlett JG. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40:100-7. Nuermberger E, Juan G, Hardick J, Bartlett JG, Auwaerter PG, Rothman RE. Quantitative PCR assay using sputum samples for rapid diagnosis of pneumococcal pneumonia in adult emergency department patients. J Clin Microbiol. 2005;43:3221-6. Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J. Bactericidal activity of the nitroimidazopyran, PA-824, in the murine model of tuberculosis. Antimicrob Agents Chemother. 2005; 49:2289-93. Nuermberger EL. Weekly Moxifloxacin and Rifapentine is More Active than the Denver Regimen in Murine Tuberculosis. Am J Respir Crit Care Med. 2005;172:1457-62. Nuermberger E, Tyagi S, Williams K, Rosenthal I, Bishai WR, Grosset JH. Rifapentine, Moxifloxacin or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model. Am J Respir Crit Care Med. 2005;172:1452-6. Nuermberger E, Helke K, Bishai WR. The Low-dose Aerosol Model of Pneumococcal Pneumonia in the Mouse: Utility for Evaluation of Antimicrobial Efficacy. Int J Antimicrob Agents 2005;26:497-503. Nuermberger EL. Potent Twice-weekly Rifapentine-containing Regimens in Murine Tuberculosis. Am J Respir Crit Care Med. 2006; 2006;74:94-101. Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, Peloquin CA, Bishai WR, Grosset JH. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in the murine model of tuberculosis. Antimicrob Agents Chemother. 2006;50:2621-5. Nuermberger E, Grosset J, McMurray DN, Karakousis PC, Lamichhane G, Bishai WR. Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs compared with mice. J Infect Dis. 2007;195:1634-42. Nuermberger E, Grosset J. Promising clinical efficacy of the combination streptomycin - rifampin for the treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother. 2007;51:4029-35. Nuermberger E, Zhang Y. Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model. J Med Microbiol. 2007;56:1047-51. Nuermberger EL. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Medicine, 2007;4:e344. Nuermberger E, Tyagi S, Bishai WR, Grosset J. In vivo validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother. 2007;51:4261-6. Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in the murine model of tuberculosis. Antimicrob Agents Chemother. 2008;52:1522-4. Nuermberger E. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in the murine model of tuberculosis. Antimicrob Agents Chemother. 2008;52:3664-8. Nuermberger EL. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med. 2008;178:989-93. Nuermberger E, Chaisson RE, Dorman SE. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother. 2008;52:4037-42. Nuermberger E. Promising anti-tuberculosis activity of the oxazolidinone PNU-100480 relative to linezolid in the murine model. Antimicrob Agents Chemother. 2009;53:1314-9. Nuermberger EL, Bishai WR. Role of the dosR/dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun. 2009;77:1230-7. Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.Am J Respir Crit Care Med. 2009;180:273-80.